Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484126 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL15529385 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL7232865 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL311527 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613189 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613207 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668549 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668550 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL24062391 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL20346210 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2022-04-28 | — | — | US | disclosed |
| EP-3921313-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020161623-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| US-10633630-B2 | Acceleration of Mycobacterium growth | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2020-04-28 | — | — | US | disclosed |
| EP-3158053-B1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9707282-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20170121672-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3158053-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | St. George's Hospital Medical School (GB) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193688-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2015-12-23 | — | — | WO | disclosed |
| US-20150315240-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-05 | — | — | US | disclosed |
| US-9017656-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-04-28 | — | — | US | disclosed |
| EP-2061886-B1 | Small cationic immunomodulatory peptides | UNIV BRITISH COLUMBIA (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127247-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, P2RY1, P2RX5 | ALDH1A1 1455/4885CYP2C19 783/4885POLB 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.